Related references
Note: Only part of the references are listed.Sticking it to KRAS: Covalent Inhibitors Enter the Clinic
Frank McCormick
CANCER CELL (2020)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Cracking KRAS
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2019)
KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
Aron Kristof Ghimessy et al.
CANCERS (2019)
KRAS: Reasons for optimism in lung cancer
C. R. Lindsay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Rho-Kinase Blockade Attenuates Podocyte Apoptosis by Inhibiting the Notch Signaling Pathway in Diabetic Nephropathy
Keiichiro Matoba et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer
Yijun Jia et al.
ONCOLOGY LETTERS (2017)
Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
Stephane Renaud et al.
BRITISH JOURNAL OF CANCER (2016)
Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
Stephane Renaud et al.
BRITISH JOURNAL OF CANCER (2015)
K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling
Man-Tzu Wang et al.
CELL (2015)
ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma
Jianxiang Chen et al.
JOURNAL OF HEPATOLOGY (2015)
Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
Helena A. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer
Wouter W. Mellema et al.
LUNG CANCER (2015)
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
John C. Hunter et al.
MOLECULAR CANCER RESEARCH (2015)
The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1
Jane Cullis et al.
CANCER CELL (2014)
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy
Mihaly Cserepes et al.
EUROPEAN JOURNAL OF CANCER (2014)
Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models
T. W. Chew et al.
ONCOGENE (2014)
KRAS: feeding pancreatic cancer proliferation
Kirsten L. Bryant et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Rho family GTPases: key players in neuronal development neuronal survival, and neurodegeneration
Trisha R. Stankiewicz et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
RHOA inactivation enhances Wnt signalling and promotes colorectal cancer
Paulo Rodrigues et al.
NATURE COMMUNICATIONS (2014)
Extracellular Signal-Regulated Kinase Regulates RhoA Activation and Tumor Cell Plasticity by Inhibiting Guanine Exchange Factor H1 Activity
Anne von Thun et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
Mark Steven Miller et al.
Frontiers in Genetics (2012)
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
M. C. Garassino et al.
ANNALS OF ONCOLOGY (2011)
Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium
Eugenia C. Pacheco-Pinedo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Dominico Vigil et al.
NATURE REVIEWS CANCER (2010)
Guanine Nucleotide Exchange Factor-H1 Regulates Cell Migration via Localized Activation of RhoA at the Leading Edge
Perihan Nalbant et al.
MOLECULAR BIOLOGY OF THE CELL (2009)
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2008)
ras oncogenes: their role in neoplasia
M. BARBACID
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Rho GTPases in cancer cell biology
Francisco M. Vega et al.
FEBS LETTERS (2008)
Wnt signalling and its impact on development and cancer
Alexandra Klaus et al.
NATURE REVIEWS CANCER (2008)
Vasopressin triggers senescence in K-ras transformed cells via RhoA-dependent downregulation of cyclin D1
Fabio L. Forti et al.
ENDOCRINE-RELATED CANCER (2007)
Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice
Surbhi Gupta et al.
CELL (2007)
Wnt/β-catenin signaling in development and disease
Hans Clevers
CELL (2006)
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer
D Arango et al.
GASTROENTEROLOGY (2005)
Convergence of Wnt, β-catenin, and cadherin pathways
WJ Nelson et al.
SCIENCE (2004)
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
S Bamford et al.
BRITISH JOURNAL OF CANCER (2004)
Rho GTPases in cell biology
S Etienne-Manneville et al.
NATURE (2002)
Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells
XF Ming et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton
M Krendel et al.
NATURE CELL BIOLOGY (2002)
Rho family proteins: coordinating cell responses
AJ Ridley
TRENDS IN CELL BIOLOGY (2001)
Signal transduction - The guanine nucleotide-binding switch in three dimensions
IR Vetter et al.
SCIENCE (2001)
Ras and Rho GTPases: A family reunion
D Bar-Sagi et al.
CELL (2000)
Share Paper
